Parasites, Hosts and Diseases

Skip to main navigation Skip to main content

OPEN ACCESS

Page Path

HOME
BROWSE ARTICLES

Author index detail contents
Kobsiri Chalermrut	2 Articles
Minor liver profile dysfunctions in Plasmodium vivax, P. malariae and P. ovale patients and normalization after treatment Noppadon Tangpukdee, Vipa Thanachartwet, Srivicha Krudsood, Nutthanej Luplertlop, Karnchana Pornpininworakij, Kobsiri Chalermrut, Sasikarn Phokham, Shigeyuki Kano, Sornchai Looareesuwan, Polrat Wilairatana Korean J Parasitol 2006;44(4):295-302. Published online December 20, 2006 DOI: https://doi.org/10.3347/kjp.2006.44.4.295 Abstract PDF Liver function tests were performed in 61 vivax, 54 malariae and 15 ovale malaria patients who were admitted to Bangkok Hospital for Tropical Diseases between 2001 and 2004. The objective of the study was to evaluate changes in hepatic biochemical indices before and after treatment with artemisinin derivatives. On admission and prior to treatment, hepatic dysfunction was found among the 3 groups. Serum liver function tests and physical examinations were performed weekly during the 28-day follow-up period. Initially elevated serum bilirubin and diminished albumin returned to normal within 2 weeks of treatment. Serum alkaline phosphatase and aminotransferases returned to within normal limits within 3 weeks. We conclude that patients with Plasmodium vivax, P. malariae and P. ovale infections had slightly elevated serum bilirubin, aminotransferase and alkaline phosphatase levels, and hypoalbuminemia. These minor abnormalities returned to normal within a few weeks after treatment with therapies based on artemisinin derivatives. Citations Citations to this article as recorded by The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study John Woodford, G. Dennis Shanks, Paul Griffin, Stephan Chalon, James S. McCarthy The American Journal of Tropical Medicine and Hygiene.2018; 98(4): 1113. CrossRef Liver injury in uncomplicated malaria: an overlooked phenomenon Brioni R. Moore EBioMedicine.2018; 37: 15. CrossRef Quantitative Proteomics Analysis of Plasmodium vivax Induced Alterations in Human Serum during the Acute and Convalescent Phases of Infection Sandipan Ray, Sandip K. Patel, Apoorva Venkatesh, Gangadhar Chatterjee, Naziya N. Ansari, Nithya J. Gogtay, Urmila M. Thatte, Prajakta Gandhe, Santosh G. Varma, Swati Patankar, Sanjeeva Srivastava Scientific Reports.2017;[Epub] CrossRef Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria Transmission Paul Griffin, Cielo Pasay, Suzanne Elliott, Silvana Sekuloski, Maggy Sikulu, Leon Hugo, David Khoury, Deborah Cromer, Miles Davenport, Jetsumon Sattabongkot, Karen Ivinson, Christian Ockenhouse, James McCarthy, Photini Sinnis PLOS Neglected Tropical Diseases.2016; 10(12): e0005139. CrossRef Clinico-pathological studies of Plasmodium falciparum and Plasmodium vivax — malaria in India and Saudi Arabia Wajihullah Khan, Haytham Zakai, Umm-e-Asma Acta Parasitologica.2014;[Epub] CrossRef Association of Heme Oxygenase 1 with the Restoration of Liver Function after Damage in Murine Malaria by Plasmodium yoelii Sumanta Dey, Somnath Mazumder, Asim Azhar Siddiqui, M. Shameel Iqbal, Chinmoy Banerjee, Souvik Sarkar, Rudranil De, Manish Goyal, Samik Bindu, Uday Bandyopadhyay, J. H. Adams Infection and Immunity.2014; 82(8): 3113. CrossRef A STUDY OF CLINICAL PROFILE IN PATIENTS WITH P.VIVAX MALARIA Apte S., Jain J., Parmar A., Apte A., Sinha U, Chanchlani R Journal of Evolution of Medical and Dental Sciences.2014; 03(03): 575. CrossRef Mice lacking inducible nitric oxide synthase develop exacerbated hepatic inflammatory responses induced by Plasmodium berghei NK65 infection Onésia Cristina Oliveira-Lima, Danielle Bernardes, Mauro Cunha Xavier Pinto, Rosa Maria Esteves Arantes, Juliana Carvalho-Tavares Microbes and Infection.2013; 15(13): 903. CrossRef Clinico-laboratory profile of severe Plasmodium vivax malaria in a tertiary care centre in Kolkata Sayantan Ray, Manjari Saha, Debojyoti Sarkar, Arunansu Talukdar, Amitava Chakraborty Tropical Parasitology.2013; 3(1): 53. CrossRef Effect of artesunate based combination therapy with homeopathic medicine china on liver and kidney of Plasmodium berghei infected mice A. Rajan, U. Bagai, S. Chandel Journal of Parasitic Diseases.2012;[Epub] CrossRef A Case of Plasmodium ovale Malaria Imported from West Africa SeJin Moon, Baek-Nam Kim, Eun-Young Kuak, Tae Hee Han Laboratory Medicine Online.2012; 2(1): 51. CrossRef Retrospective analysis of vivax malaria patients presenting to tertiary referral centre of Uttarakhand Saurabh Srivastava, Sohaib Ahmad, Nadia Shirazi, Sanjiv Kumar Verma, Prashant Puri Acta Tropica.2011; 117(2): 82. CrossRef Ictericia y hepatopatía en el paciente con malaria Ana del Mar Cortina, Alberto Tobón Infectio.2010; 14(4): 277. CrossRef Clinical Features of Children Hospitalized with Malaria—A Study from Bikaner, Northwest India Dhanpat Kumar Kochar, Ashish Das, Shilpi Garg, Sanjay Kumar Kochar, Ghanshyam Singh Sengar, Gajanand Singh Tanwar, Anjana Gupta, Abhishek Kochar, Deepak Pakalapati, Vishal Saxena, Poonam Chand Khatri, Sheetal Middha, Jyoti Acharya The American Journal of Tropical Medicine and Hygiene.2010; 83(5): 981. CrossRef Chloroquine pharmacokinetics in pregnant and nonpregnant women with vivax malaria Sue Jean Lee, Rose McGready, Christine Fernandez, Kasia Stepniewska, Moo Koo Paw, Samuel Jacher Viladpai-nguen, Kyaw Lay Thwai, Leopoldo Villegas, Pratap Singhasivanon, Brian M. Greenwood, Nicholas J. White, François Nosten European Journal of Clinical Pharmacology.2008; 64(10): 987. CrossRef Bilirubin inhibits Plasmodium falciparum growth through the generation of reactive oxygen species Sanjay Kumar, Mithu Guha, Vinay Choubey, Pallab Maity, Kumkum Srivastava, Sunil K. Puri, Uday Bandyopadhyay Free Radical Biology and Medicine.2008; 44(4): 602. CrossRef 8,391 View 132 Download Crossref Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmodium vivax malaria in Thailand Srivicha Krudsood, Polrat Wilairatana, Noppadon Tangpukdee, Kobsiri Chalermrut, Siripun Srivilairit, Vipa Thanachartwet, Sant Muangnoicharoen, Natthanej Luplertlop, Gary M. Brittenham, Sornchai Looareesuwan Korean J Parasitol 2006;44(3):221-228. Published online September 20, 2006 DOI: https://doi.org/10.3347/kjp.2006.44.3.221 Abstract PDF We conducted a study to compare the safety and tolerability of anti-relapse drugs elubaquine and primaquine against Plasmodium vivax malaria. After standard therapy with chloroquine, 30 mg/kg given over 3 days, 141 patients with P. vivax infection were randomized to receive primaquine or elubaquine. The 2 treatment regimens were primaquine 30 mg once daily for 7 days (group A, n = 71), and elubaquine 25 mg once daily for 7 days (group B, n = 70). All patients cleared parasitemia within 7 days after chloroquine treatment. Among patients treated with primaquine, one patient relapsed on day 26; no relapse occurred with elubaquine treatement. Both drugs were well tolerated. Adverse effects occurred only in patients with G6PD deficiency who were treated with primaquine (group A, n = 4), whose mean hematocrit fell significantly on days 7, 8 and 9 (P = 0.015, 0.027, and 0.048, respectively). No significant change in hematocrit was observed in patients with G6PD deficiency who were treated with elubaquine (group B, n = 3) or in patients with normal G6PD. In conclusion, elubaquine, as anti-relapse therapy for P. vivax malaria, was as safe and well tolerated as primaquine and did not cause clinically significant hemolysis. Citations Citations to this article as recorded by Risk of hemolysis in Plasmodium vivax malaria patients receiving standard primaquine treatment in a population with high prevalence of G6PD deficiency Huaie Liu, Weilin Zeng, Pallavi Malla, Chengqi Wang, Seetha Lakshmi, Kami Kim, Lynette Menezes, Zhaoqing Yang, Liwang Cui Infection.2023; 51(1): 213. CrossRef Plasmodium cynomolgi in humans: current knowledge and future directions of an emerging zoonotic malaria parasite Loick P. Kojom Foko, Amit Kumar, Joseph Hawadak, Vineeta Singh Infection.2023; 51(3): 623. CrossRef The medication for pneumocystis pneumonia with glucose-6-phosphate dehydrogenase deficiency patients Ziyu Zhang, Qinhui Li, Xiaoyan Shen, Lankai Liao, Xia Wang, Min Song, Xi Zheng, Yulian Zhu, Yong Yang Frontiers in Pharmacology.2022;[Epub] CrossRef G6PD Variants and Haemolytic Sensitivity to Primaquine and Other Drugs Germana Bancone, Cindy S. Chu Frontiers in Pharmacology.2021;[Epub] CrossRef Targeting Gametocytes of the Malaria Parasite Plasmodium falciparum in a Functional Genomics Era: Next Steps Jyotsna Chawla, Jenna Oberstaller, John H. Adams Pathogens.2021; 10(3): 346. CrossRef Recent Advances in Transmission-Blocking Drugs for Malaria Elimination Ishan Wadi, Mahendra Nath, Anupkumar R Anvikar, Pargat Singh, Abhinav Sinha Future Medicinal Chemistry.2019; 11(23): 3047. CrossRef G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients Sara Avalos, Rosa E. Mejia, Engels Banegas, Cesar Salinas, Lester Gutierrez, Marcela Fajardo, Suzeth Galo, Alejandra Pinto, Angel Mejia, Gustavo Fontecha Malaria Journal.2018;[Epub] CrossRef A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications Hazem Elewa, Kyle John Wilby European Journal of Drug Metabolism and Pharmacokinetics.2017; 42(5): 745. CrossRef Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies Olalekan A. Uthman, Patricia M. Graves, Rachel Saunders, Hellen Gelband, Marty Richardson, Paul Garner Malaria Journal.2017;[Epub] CrossRef Systematic review of the clinical manifestations of glucose-6-phosphate dehydrogenase deficiency in the Greater Mekong Subregion: implications for malaria elimination and beyond Ken Ing Cherng Ong, Hodaka Kosugi, Sophea Thoeun, Hitomi Araki, Moe Moe Thandar, Moritoshi Iwagami, Bouasy Hongvanthong, Paul T Brey, Shigeyuki Kano, Masamine Jimba BMJ Global Health.2017; 2(3): e000415. CrossRef Evaluation of Efficacy of Chloroquine for Plasmodium Vivax Infection Using Parasite Clearance Times: A 10-Year Study and Systematic Review Hariharan Subramony, Noppadon Tangpukdee, Srivicha Krudsood, Kittiyod Poovorawan, Sant Muangnoicharoen, Polrat Wilairatana Annals of the Academy of Medicine, Singapore.2016; 45(7): 303. CrossRef Enantioselective Pharmacokinetics of Primaquine in Healthy Human Volunteers Babu L Tekwani, Bharathi Avula, Rajnish Sahu, Narayan D Chaurasiya, Shabana I Khan, Surendra Jain, Pius S Fasinu, H.M.T. Bandara Herath, Donald Stanford, N.P. Dhammika Nanayakkara, James D McChesney, Travis W Yates, Mahmoud A ElSohly, Ikhlas A Khan, Larry Drug Metabolism and Disposition.2015; 43(4): 571. CrossRef “Recycling” Classical Drugs for Malaria Cátia Teixeira, Nuno Vale, Bianca Pérez, Ana Gomes, José R. B. Gomes, Paula Gomes Chemical Reviews.2014; 114(22): 11164. CrossRef KAI407, a Potent Non-8-Aminoquinoline Compound That Kills Plasmodium cynomolgi Early Dormant Liver Stage ParasitesIn Vitro Anne-Marie Zeeman, Sandra M. van Amsterdam, Case W. McNamara, Annemarie Voorberg-van der Wel, Els J. Klooster, Alexander van den Berg, Edmond J. Remarque, David M. Plouffe, Geert-Jan van Gemert, Adrian Luty, Robert Sauerwein, Kerstin Gagaring, Rachel Borb Antimicrobial Agents and Chemotherapy.2014; 58(3): 1586. CrossRef Novel approaches in antimalarial drug discovery Jana Held, Andrea Kreidenweiss, Benjamin Mordmüller Expert Opinion on Drug Discovery.2013; 8(11): 1325. CrossRef Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine Gawrie NL Galappaththy, Prathap Tharyan, Richard Kirubakaran Cochrane Database of Systematic Reviews.2013;[Epub] CrossRef Effects of Antimalarial Molecules on the Gametocyte Stage of Plasmodium falciparum: The Debate Odile Dechy-Cabaret, Françoise Benoit-Vical Journal of Medicinal Chemistry.2012; 55(23): 10328. CrossRef Targeting the Liver Stage of Malaria Parasites: A Yet Unmet Goal Tiago Rodrigues, Miguel Prudêncio, Rui Moreira, Maria M. Mota, Francisca Lopes Journal of Medicinal Chemistry.2012; 55(3): 995. CrossRef PharmGKB summary Ellen M. McDonagh, Caroline F. Thorn, José M. Bautista, Ilan Youngster, Russ B. Altman, Teri E. Klein Pharmacogenetics and Genomics.2012; 22(3): 219. CrossRef New approaches in antimalarial drug discovery and development: a review Anna Caroline C Aguiar, Eliana MM da Rocha, Nicolli B de Souza, Tanos CC França, Antoniana U Krettli Memórias do Instituto Oswaldo Cruz.2012; 107(7): 831. CrossRef Plasmodium vivax treatments Ric N. Price, Nicholas M. Douglas, Nicholas M. Anstey, Lorenz von Seidlein Current Opinion in Infectious Diseases.2011; 24(6): 578. CrossRef Feeding the Antimalarial Pipeline Martin Schlitzer, Regina Ortmann ChemMedChem.2010; 5(11): 1837. CrossRef Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination Timothy N.C. Wells, Jeremy N. Burrows, J. Kevin Baird Trends in Parasitology.2010; 26(3): 145. CrossRef Blocking Plasmodium falciparum Malaria Transmission with Drugs: The Gametocytocidal and Sporontocidal Properties of Current and Prospective Antimalarials Anthony E. Kiszewski Pharmaceuticals.2010; 4(1): 44. CrossRef Medications and Glucose-6-Phosphate Dehydrogenase Deficiency Ilan Youngster, Lidia Arcavi, Renata Schechmaster, Yulia Akayzen, Hen Popliski, Janna Shimonov, Svetlana Beig, Matitiahu Berkovitch Drug Safety.2010; 33(9): 713. CrossRef A pre-emptive strike against malaria's stealthy hepatic forms Dominique Mazier, Laurent Rénia, Georges Snounou Nature Reviews Drug Discovery.2009; 8(11): 854. CrossRef Resistance to Therapies for Infection byPlasmodium vivax J. Kevin Baird Clinical Microbiology Reviews.2009; 22(3): 508. CrossRef 8-Aminoquinolines: future role as antiprotozoal drugs Babu L Tekwani, Larry A Walker Current Opinion in Infectious Diseases.2006; 19(6): 623. CrossRef 9,864 View 110 Download Crossref